Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Vaccine Designed Equipment Supplied In Europe
10 equipment items found
by:Evaxion Biotech A/S based inHørsholm, DENMARK
RAVEN is our third proprietary AI platform that brings our unique, machine learning approach to vaccine design and development for viral diseases. RAVEN combines the essential AI tools from our PIONEER platform with structural bioinformatic tools from EDEN to arrive at a novel potent T- and B-cell vaccine design for emerging and ...
Manufactured by:SureChill based inCardiff, UNITED KINGDOM
The GVR50 AC medical refrigerator, powered by the innovative SureChill technology, ensures precise temperature control with no risk of freezing, making it ideal for storing temperature-sensitive drugs and vaccines. Designed for energy efficiency, it operates on mains electric power at both 220V and 110V, with a holdover time exceeding 7 days and requiring only ...
Manufactured by:Treos Bio Limited based inLondon, UNITED KINGDOM
Using our proprietary computational vaccine design technology, we have developed a PolyPEPI preventive peptide vaccine against COVID-19 (SARS-CoV-2). The design of PolyPEPI-SCoV-2 exploits our knowledge on genetic heterogeneity of individuals and ethnicities. PolyPEPI-SCoV-2 vaccine can elicit broad and ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
With the ongoing development of our NanoFlu™ and RSV F vaccines, a strong rationale exists for developing a combination respiratory vaccine that is designed to protect susceptible populations against both diseases. Although testing is at an early stage, we believe that a combination vaccine against both seasonal influenza ...
Manufactured by:Oxford Vacmedix UK Limited based inOxford, UNITED KINGDOM
Tumours can often avoid being targeted by these T Cells by looking like a cell found normally in the body often referred to as “self”. If a group of T Cells can be encouraged to recognise these tumours as foreign and not self then they will attack the tumour and provide an effective treatment against it. Injecting a preparation that stimulates these T Cells effectively vaccinates the ...
Manufactured by:Polar Thermal Packaging Ltd based inWarminster, UNITED KINGDOM
The Vaccine – BluKoat Insulated Transport Bag is a cutting-edge solution designed for the secure and efficient transportation of vaccines. This product, designed by Polar Thermal Packaging, offers a sophisticated insulation system using patented Polar Thermal material with a thickness of 45mm to provide effective thermal ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
ImmunoBody vaccines are designed to generate potent T cell responses capable of a broad anti-tumour effect. They are DNA vaccines that encode a protein in the form of an antibody, but the parts of the antibody that would normally bind to the target protein are replaced with epitopes from a cancer ...
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TNX-1850 is the planned new version of the TNX-1800 vaccine that encodes spike protein from SARS-CoV-2 BA.2 ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...